Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375734 | 1.00 | GPR119 (0.75) | GPR119CYP2C9 | |
| SCHEMBL2116785 | 0.91 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL2116786 | 0.91 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL12295650 | 0.86 | GPR119 (0.66) | GPR119CYP2C9 | |
| SCHEMBL4491635 | 0.86 | GPR119 (1.00) | GPR119CYP2C9 | |
| SCHEMBL10170984 | 0.85 | GPR119 (0.56) | GPR119CYP2C9 | |
| SCHEMBL10170845 | 0.83 | GPR119 (0.54) | GPR119CYP2C9 | |
| SCHEMBL12414061 | 0.82 | GPR119 (0.57) | GPR119CYP2C9 | |
| SCHEMBL12414235 | 0.81 | GPR119 (0.79) | GPR119CYP2C9 | |
| SCHEMBL12414017 | 0.81 | GPR119 (0.79) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | claimed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| US-20120095028-A1 | 3-OXA-7-AZABICYCLO[3.3.1]NONANES | PFIZER INC. | 2012-04-19 | — | — | US | claimed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | claimed |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20120095028-A1 | 3-OXA-7-AZABICYCLO[3.3.1]NONANES | PFIZER INC. | 2012-04-19 | — | — | US | disclosed |
| EP-2408780-A2 | 3-OXA-7-AZABICYCLOÝ3.3.1¨NONANES | Pfizer Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| WO-2010106457-A2 | 3-OXA-7-AZABICYCLO[3.3.1]NONANES | PFIZER INC. (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095028-A1 | 3-OXA-7-AZABICYCLO[3.3.1]NONANES | GPR119, GPR27, GPBAR1 | GPR119 1/4885CYP2C9 835/4885 |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | GPR119, DPP4, GLP1R | GPR119 1/4885CYP2C9 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.